| Clinical Focus | Stage Development | |||||
|---|---|---|---|---|---|---|
| Drug | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Fibrosis | ||||||
| Belapectin | NASH Cirrhosis | |||||
| NASH Advanced Fibrosis | ||||||
| Lung, Kidney | ||||||
| Arrhythmia, Pulmonary Arterial Hypertension | ||||||
| Cancer Immunotherapy (combination therapy) | ||||||
| Belapectin + Keytruda | Melanoma + Head/Neck Cancer | |||||
| Plaque Psoriasis | ||||||
| Belapectin | Moderate-severe | |||||
| Oral Galectin-3 Inhibitors | ||||||
| Discovery program to identify subcutaneous and oral forms of carbohydrates and oral small molecules | ||||||
Learn more about our development program here.
Galectin Therapeutics seeks to broaden the scope of galectin-related disease indications and science. Therefore, we have established a number of academic collaborations with investigators and welcome opportunities to work with additional investigators. Click here to contact us.